Your browser doesn't support javascript.
loading
Leveraging in vitro and pharmacokinetic models to support bench to bedside investigation of XTMAB-16 as a novel pulmonary sarcoidosis treatment.
Offman, Elliot; Singh, Noopur; Julian, Mark W; Locke, Landon W; Bicer, Sabahattin; Mitchell, Jonah; Matthews, Thomas; Anderson, Kirsten; Crouser, Elliott D.
Afiliación
  • Offman E; Certara, Princeton, NJ, United States.
  • Singh N; Xentria, Inc., Chicago, IL, United States.
  • Julian MW; Division of Pulmonary, Critical Care and Sleep Medicine, The Dorothy M. Davis Heart and Lung Research Institute, Columbus, OH, United States.
  • Locke LW; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
  • Bicer S; Department of Biomedical Engineering, The Ohio State University, Columbus, OH, United States.
  • Mitchell J; Department of Biomedical Engineering, The Ohio State University, Columbus, OH, United States.
  • Matthews T; Department of Biomedical Engineering, The Ohio State University, Columbus, OH, United States.
  • Anderson K; Xentria, Inc., Chicago, IL, United States.
  • Crouser ED; Xentria, Inc., Chicago, IL, United States.
Front Pharmacol ; 14: 1066454, 2023.
Article en En | MEDLINE | ID: mdl-37021060
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos